Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173992 | 1.00 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2672091 | 1.00 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3172172 | 0.86 | FPR2 (0.47) | HDAC4HDAC1HDAC7HDAC2HDAC8 | |
| SCHEMBL3172158 | 0.86 | FPR2 (0.47) | HDAC4HDAC1HDAC7HDAC2HDAC8 | |
| SCHEMBL4531134 | 0.86 | FPR2 (0.47) | HDAC4HDAC1HDAC7HDAC2HDAC8 | |
| SCHEMBL18247907 | 0.85 | PDE2A (0.50) | CNR2NPC1PDE2A | |
| SCHEMBL7658688 | 0.85 | KEAP1 (0.48) | CNR2ALDH1A1PDE2AFOLH1 | |
| SCHEMBL7495873 | 0.85 | CNR2 (0.40) | HDAC4HDAC7HDAC5CNR2MEN1 | |
| SCHEMBL20266696 | 0.85 | PDE2A (0.50) | CNR2NPC1PDE2A | |
| SCHEMBL4076538 | 0.82 | PDE2A (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| US-8604039-B2 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-7648988-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-01-19 | — | — | US | disclosed |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | DOLLINGER HORST | 2008-06-26 | — | — | US | disclosed |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | PTGER4, PTGER1, PDE4A | HDAC3 1471/4885HDAC4 325/4885HDAC1 1483/4885 |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | HDAC3 3008/4885HDAC4 3611/4885HDAC1 2359/4885 |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | DPYD, TYMS, TPMT | HDAC3 2817/4885HDAC4 3971/4885HDAC1 3230/4885 |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | HDAC3 2455/4885HDAC4 2887/4885HDAC1 3559/4885 |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | HDAC3 2455/4885HDAC4 2887/4885HDAC1 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.